Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus METASTRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus METASTRON.
INDIUM IN 111 CHLORIDE vs METASTRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical